Evidence map›Paper›PMID 38538970›Full record

ArticlePharmaceutical research2024

Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia.

Leiah J Brigitha, Veerle Mondelaers, Yiwei Liu, Birgitte K Albertsen, Beata Zalewska-Szewczyk, Carmelo Rizzari, Rishi S Kotecha, Rob Pieters, Alwin D R Huitema, Inge M van der Sluis

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Haematologica · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Leiah J BrigithaPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, Netherlands.ORCID http://orcid.org/0000-0003-2816-2610
Veerle MondelaersDepartment of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent University, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
Yiwei LiuDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, USA.
Birgitte K AlbertsenDepartment of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, 8200, Aarhus, Denmark.
Beata Zalewska-SzewczykDepartment of Pediatrics, Medical University of Lodz, Oncology & Hematology, 91-738, Lodz, Poland.
Carmelo RizzariDepartment of Pediatrics, University of Milano-Bicocca, Piazza Dell'Ateneo Nuovo, 1, Milano, Italy.
Rishi S KotechaDepartment of Clinical Haematology, Oncology, Blood and Marrow Transplantation, Perth Children's Hospital, Perth, Australia.
Rob PietersPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, Netherlands.
Alwin D R Huitema *Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, Netherlands.
Inge M van der Sluis *Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, Netherlands. i.m.vandersluis@prinsesmaximacentrum.nl.

Funding

Belgian Federal Public Service of Health Cancer Plan Action 29
6 · The paper itself

Abstract

backgroundPEGasparaginase is known to be a critical drug for treating pediatric acute lymphoblastic leukemia (ALL), however, there is insufficient evidence to determine the optimal dose for infants who are less than one year of age at diagnosis. This international study was conducted to identify the pharmacokinetics of PEGasparaginase in infants with newly diagnosed ALL and gather insight into the clearance and dosing of this population.

methodsInfants with ALL who received treatment with PEGasparaginase were included in our population pharmacokinetic assessment employing non-linear mixed effects modelling (NONMEM).

results68 infants with ALL, with a total of 388 asparaginase activity samples, were included. PEGasparaginase doses ranging from 400 to 3,663 IU/m

conclusionThe pharmacokinetics of PEGasparaginase in infants diagnosed under one year of age with ALL is comparable to that of older children (1-18 years). We recommend a PEGasparaginase dosing at 1,500 IU/m

Indexed as

Antineoplastic AgentsPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentAsparaginaseChildChild, PreschoolDrug MonitoringHumansInfantAntineoplastic AgentsAsparaginaseacute lymphoblastic leukemiainfantPEgasparaginasepopulation pharmacokinetics

Identifiers

PMID38538970

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.